Valuation: PolyPeptide Group AG

Market Cap 1.44B 1.6B 1.33B 1.21B 2.28B 150B 2.34B 15.96B 6.36B 80.5B 6.01B 5.88B 256B P/E 2026 *
53.8x
P/E 2027 * 28.6x
Enterprise Value 1.54B 1.71B 1.43B 1.29B 2.44B 160B 2.51B 17.07B 6.8B 86.13B 6.43B 6.29B 274B EV / Sales 2026 *
3.08x
EV / Sales 2027 * 2.73x
Free-Float
98.54%
Yield 2026 *
-
Yield 2027 * 0.15%
1 week-5.16%
Current month-3.81%
1 month-7.87%
3 months-8.08%
6 months+2.54%
Current year+54.79%
1 week 40.05
Extreme 40.05
41.35
1 month 40.05
Extreme 40.05
44.3
Current year 23.1
Extreme 23.1
50.1
1 year 21.8
Extreme 21.8
50.1
3 years 13.22
Extreme 13.22
50.1
5 years 13.22
Extreme 13.22
146
10 years 13.22
Extreme 13.22
147.4
Manager TitleAgeSince
Chief Executive Officer 54 2023-04-11
Director of Finance/CFO 54 2024-01-01
Chief Tech/Sci/R&D Officer 54 -
Director TitleAgeSince
Director/Board Member 73 2005-12-31
Chairman 69 2021-03-31
Director/Board Member 62 2020-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
11/13/23 Buy 2,500 0.0075%
10/12/23 Buy 159,959 0.4829%
4/6/23 Buy 45,842 0.1384%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-5.16%+71.55%+96.31% 1.61B
+0.35%+1.98%+48.69%+140.47% 1,276B
-0.13%+5.35%+48.83%+90.43% 676B
+0.37%+3.14%+34.87%+112.84% 519B
+0.02%+2.79%+44.10%+69.76% 388B
-0.59%+1.73%+69.66%+45.16% 365B
-1.29%+0.94%+29.88%+58.29% 307B
+0.09%+0.99%+5.87%+37.72% 287B
+0.62%+1.49%+44.63%+75.12% 252B
-0.67%+1.35%+43.66%+123.56% 212B
Average -0.28%+1.59%+44.17%+84.97% 428B
Weighted average by Cap. -0.11%+2.51%+43.71%+97.22%

Financials

2026 *2027 *
Net sales 502M 557M 463M 419M 793M 52.14B 814M 5.55B 2.21B 27.98B 2.09B 2.04B 88.93B 576M 639M 532M 481M 911M 59.84B 934M 6.37B 2.54B 32.12B 2.4B 2.35B 102B
Net income 23.5M 26.08M 21.7M 19.64M 37.15M 2.44B 38.12M 260M 104M 1.31B 97.8M 95.69M 4.16B 45.23M 50.19M 41.75M 37.79M 71.49M 4.7B 73.35M 500M 199M 2.52B 188M 184M 8.01B
Net Debt 101M 112M 93.19M 84.36M 160M 10.49B 164M 1.12B 445M 5.63B 420M 411M 17.89B 131M 145M 121M 109M 207M 13.6B 212M 1.45B 577M 7.3B 545M 533M 23.19B
Projected Income Statement - Annual - PolyPeptide Group AG
Logo PolyPeptide Group AG
Polypeptide Group AG is a Switzerland-based Contract Development & Manufacturing Organization (CDMO) focusing on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, drugs in clinical development as well as in generic products.
Employees
1,460
Date Price Change Volume
26-11-11 CHF 40.40 0.00% 7,433
26-11-10 CHF 40.40 +0.12% 8,948
26-11-09 CHF 40.35 +0.75% 6,355
26-11-06 CHF 40.05 -1.11% 21,455
26-11-05 CHF 40.50 -2.06% 17,693
Trader
Investor
Global
Quality
ESG MSCI
A
MarketScreener Ratings - PolyPeptide Group AG
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
6
Last Close Price
43.73EUR
Average target price
46.32EUR
Spread / Average Target
+5.93%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - PolyPeptide Group AG
  1. Stock Market
  2. Stocks
  3. PPGN Stock